In November, Shinya Yamanaka of Kyoto University and colleagues announced they had reprogrammed human skin cells to have the multiple potency of stem cells culled from human embryos.
Stem cells are early cells that differentiate into one of the 220 different types of cells in the body.
Medical researchers hope that one day, these cells can be grown in a lab dish to become specific replacement tissue to replenish organs ravaged by disease or damaged in accidents or warfare.
Yamanaka's team used a retrovirus to deliver four genes into skin cells taken from a mouse and an adult human.
Turning the clock back
In essence, this turned the clock back so that these cells lost their differentiated profile and became so-called induced pluripotent stem cells, or iPS.
Reporting in Nature, a team led by George Daley of the Children's Hospital, in Boston, Massachusetts, say they have been able to use the same four genes to derive iPS from foetal lung and skin cells, from neo-natal skin cells as well as from skin samples taken from a healthy human volunteer.
The research is important as it marks a step forward to "patient-specific" stem cells - in other words, transplanted stem cells that carry the same genetic code as the patient and thus cannot be rejected as alien by the body's immune system, they say.
The researchers also found that they could generate iPS without a cancer gene called c-Myc that has been implicated in tumours in many lab mice in earlier experiments.
That replicates a similar finding by Yamanaka's own team, published after the first breakthrough was reported.
The researchers stress, though, that many hurdles lie on the road ahead before iPS is certified as safe and effective and can be used to grow replenishment tissue.
"Clinical success with human iPS cells must await the development of methods that avoid potentially harmful genetic modification," they write, saying that "a worthy goal" would be to find biochemicals to replace gene infiltration for inducing iPS. – (Sapa/AFP)